Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 48

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 48
---
 20-F for the year
ended December 31, 2023. Consequently, we were not compliant with the periodic reporting requirements under the Exchange Act at such
time. We cannot guarantee that in the future our reporting will always be timely. Our failure to timely file future periodic reports
with the SEC could subject us to enforcement action by the SEC and shareholder lawsuits and could eventually result in the delisting
of our Class A Ordinary Shares from Nasdaq, regulatory sanctions from the SEC, and/or the breach of covenants in our credit facilities
or of any preferred equity or debt securities we may issue in the future, any of which could have a material adverse impact on our operations
and your investment in our Class A Ordinary Shares, and our ability to register with the SEC public offerings of our securities for our
benefit or the benefit of our security holders. Additionally, our failure to file our past periodic reports and future periodic reports
has resulted in and could result in investors not receiving adequate information regarding us with which to make investment decisions.
As a result, investors may not have access to current or timely financial information about our business.

If we are unable to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted.

On October 8, 2024, the Company
received a deficiency letter (“Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the “Minimum Bid Price Rule”). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive
business days, the Company’s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the
Minimum Bid Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance
with the Minimum Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company’s Class
A Ordinary Shares is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation
of compliance with this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its
issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and un